

# TABLE OF CONTENTS

Preface .....	iii
Disclosure of Potential Conflicts of Interest .....	iv
Continuing Pharmacy Education and Recertification Instructions. v	

Pharmacy Practice I .....	1
Faculty Panel .....	3

## ADVERSE DRUG REACTIONS

By *Stephanie N. Schatz, Pharm.D., BCPS;*  
and *Robert J. Weber, Pharm.D., BCPS*

Learning Objectives.....	5
Introduction.....	5
Baseline Knowledge Statements .....	5
Additional Readings .....	5
Abbreviations in This Chapter .....	6
Detection of ADRs.....	6
Causality Assessment of Suspected ADRs .....	9
Populations at Greatest Risk.....	11
Reporting of ADRs in the United States .....	15
International ADR Reporting.....	17
Reducing Hospital Readmissions from ADRs.....	19
Developing an ADR Surveillance and Reporting Program .....	19
Conclusion.....	20
References.....	21

## HEALTH COACHING

By *Nora Stelter, Pharm.D., CHWC;* and  
*Kristen L. DiDonato, Pharm.D., BCACP*

Learning Objectives.....	29
Introduction.....	29
Baseline Knowledge Statements .....	29
Additional Readings .....	29
Abbreviations in This Chapter .....	30
An Emerging Field in Health and Wellness .....	30
The Health Coaching Process.....	32
Health Coaching Theories and Skills.....	35
Conclusion.....	38
References.....	39

## BIOTERRORISM

By *Peter D. Anderson, Pharm.D., BCPP, CMI-IV*

Learning Objectives.....	45
Introduction.....	45
Baseline Knowledge Statements .....	45
Additional Readings .....	45
Abbreviations in This Chapter .....	46
History of Bioterrorism .....	47
Indicators of Bioterrorism .....	48
Role of Government Agencies.....	49
Bacterial Agents.....	51
Viral Agents.....	57
Toxins.....	59

Pulmonary Chemical Weapons vs. Biological Weapons .....	61
Psychological Aspects of Bioterrorism.....	61
Role of Pharmacists.....	62
Conclusion.....	63
References.....	63

Central Nervous System I .....	69
Faculty Panel .....	71

## HEADACHE

By *Amy B. Werremeyer, Pharm.D., BCPP;* and *Amy M. VandenBerg,*  
*Pharm.D., BCPP*

Learning Objectives.....	73
Introduction.....	73
Baseline Knowledge Statements .....	73
Additional Readings .....	73
Abbreviations in This Chapter .....	74
Classification of Headache Disorders .....	74
Diagnosis and Pathophysiology.....	74
Diagnostics and Imaging.....	77
Quality Patient Care .....	77
Patient Education .....	92
References.....	92

## CHRONIC PAIN

By *Sandra L. DiScala, Pharm.D., BCPS;* and  
*Michelle D. Lesé, Pharm.D., BCPS*

Learning Objectives.....	99
Introduction.....	99
Baseline Knowledge Statements .....	99
Additional Readings .....	99
Abbreviations in This Chapter .....	100
Pathophysiology .....	100
Assessment of Pain.....	100
Treatment of Pain .....	104
Monitoring.....	113
Clinical Practice Policies and Updates.....	115
Conclusion.....	117
References.....	117

## PRESCRIPTION DRUG ABUSE

By *CAROL A. OTT, PHARM.D., BCPP*

Learning Objectives.....	125
Introduction.....	125
Baseline Knowledge Statements .....	125
Additional Readings .....	125
Abbreviations in This Chapter .....	126
National Organizations and Legislation Addressing Prescription Drug Abuse .....	127
State Policies and Regulations.....	129
Impact of Prescription Drug Prescribing Legislation .....	131
Factors Affecting Prescription Drug Abuse.....	132

Treatment of Substance Use Disorders .....	133
DSM-5 Criteria for the Diagnosis of Substance Use Disorders .....	135
Select Prescription Drugs of Abuse.....	136
Conclusion.....	139
References.....	140
Central Nervous System II .....	147
Faculty Panel .....	149

## SLEEP DISORDERS

By *Mei T. Liu, Pharm.D., BCPP; and Megan E. Maroney, Pharm.D., BCPP*

Learning Objectives.....	151
Introduction.....	151
Baseline Knowledge Statements .....	151
Additional Readings .....	151
Abbreviations in This Chapter .....	152
Insomnia.....	152
Narcolepsy.....	156
Obstructive Sleep Apnea.....	159
REM Sleep Behavior Disorder.....	161
Movement Disorders of Sleep .....	162
Treatment Considerations in Special Populations .....	167
New and Emerging Therapies.....	170
Conclusion.....	170
References.....	171

## SCHIZOPHRENIA

By *Sarah E. Grady, Pharm.D., BCPS, BCPP*

Learning Objectives.....	179
Introduction.....	179
Baseline Knowledge Statements .....	179
Recommended antipsychotic monitoring values .....	179
Additional Readings .....	179
Abbreviations in This Chapter .....	180
Treatment Goals.....	181
Adverse Effects.....	188
Antipsychotic Pharmacokinetics and Potential Drug Interactions.....	192
Special Populations.....	193
Conclusion.....	194
References.....	195

## AUTISM SPECTRUM DISORDER

By *JUSTIN W. COLE, PHARM.D., BCPS*

LEARNING OBJECTIVES.....	201
Introduction.....	201
Baseline Knowledge Statements .....	201
Additional Readings .....	201
Abbreviations in This Chapter .....	202
Epidemiology.....	202
Pathophysiology.....	202
Screening and Diagnosis.....	202
Treatment Goals.....	203
Nonpharmacologic Treatment.....	203

Pharmacotherapy.....	205
Monitoring.....	214
Complementary and Alternative Treatments .....	215
Emerging Therapies .....	216
Transitions of Care .....	216
Patient and Family Education .....	216
Conclusion.....	217
References.....	217

Central Nervous System III .....	227
Faculty Panel .....	229

## NEUROREHABILITATION

By *DEHUTI A. PANDYA, PHARM.D., BCPS; AND CHRISTINE HULS, PHARM.D., BCPS*

LEARNING OBJECTIVES.....	231
Introduction.....	231
Stroke.....	231
Baseline Knowledge Statements .....	231
Additional Readings .....	231
Abbreviations in This Chapter .....	232
Traumatic Brain Injury.....	234
Spinal Cord Injury.....	238
Seizures.....	241
Spasticity .....	242
Depression and Mood .....	245
Heterotopic Ossification.....	246
Patient and Family Education .....	247
Conclusion.....	247
References.....	248

## MULTIPLE SCLEROSIS

By *SHILPA A. KINIKAR, PHARM.D., BCPS*

LEARNING OBJECTIVES.....	255
Introduction.....	255
Baseline Knowledge Statements .....	255
Additional Readings .....	255
Abbreviations in This Chapter .....	256
Clinical Management.....	259
Special Populations.....	273
Conclusion.....	274
References.....	275

## MOVEMENT DISORDERS

By *Robin N. Hieber, Pharm.D., BCPP; and Jacquelyn E. Canning, Pharm.D., BCPP*

Learning Objectives.....	285
Introduction.....	285
Baseline Knowledge Statements .....	285
Additional Readings .....	285
Abbreviations in This Chapter .....	286
Essential Tremor.....	286
Parkinson Disease.....	286
Drug-Induced Movement Disorders.....	299
References.....	306